Stablepharma sign exclusive supply agreement to produce the world’s first fridge-free Tetanus diphtheria vaccine

Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) European vaccine manufacturer, are delighted to announce that we have signed a definitive agreement for the exclusive bulk supply and commercialisation of the Tetanus diphtheria vaccine, on September 20th, 2022. This agreement follows the head of terms signed in 2022 and consolidates the relationship […]

Read More

New Data demonstrates StablevaX™-Td Vaccine Stable after 12 months at +45°C

Stablepharma and BB-NCIPD Ltd (Bul Bio) establish thermostability of StablevaX™-Td Vaccine After Exposure to +45°C for 12 months In-vitro and In-vivo Studies Pave the Way for Fridge-Free Vaccines Stablepharma Ltd and BB-NCIPD Ltd (Bul Bio) formed a strategic partnership in 2021 to produce the world’s first fridge-free Tetanus diphtheria (Td) vaccine, StablevaX™-Td. Encouraging potency and […]

Read More